The development and use of quality-of-life measures to evaluate health outcomes in Japan

Shunichi Fukuhara, Naoki Ikegami, George W. Torrance, Shuzo Nishimura, Michael Drummond, François Schubert

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Health outcomes measurement forms a key aspect of data collection for economic evaluations. Quality-of-life instruments provide a measure of patient-focused health outcomes. Such instruments, including the EuroQoL questionnaire (EQ-5D) and the Short-form 36 (SF-36) are already being used in Japan. Utility instruments provide an alternative way of measuring quality of life for use in economic analyses. At present, utility measurement in Japan is limited to scores derived from the EQ-5D. Although the SF-36 was designed as a health profile measure, it has since been tested for use as a utility measure, with valuation of items now being undertaken in Japan. Utility measurement in Japan is likely to be advanced further by the validation and introduction of the Health Utilities Index. The experiences of other countries provide the opportunity for Japan to learn how utility scores may be used in cost-utility analyses of healthcare technologies.

Original languageEnglish
Pages (from-to)17-23
Number of pages7
JournalPharmacoEconomics
Volume20
Issue numberSUPPL. 2
Publication statusPublished - 2002

Fingerprint

Japan
Quality of Life
Health
Cost-Benefit Analysis
Economics
Technology
Delivery of Health Care

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Fukuhara, S., Ikegami, N., Torrance, G. W., Nishimura, S., Drummond, M., & Schubert, F. (2002). The development and use of quality-of-life measures to evaluate health outcomes in Japan. PharmacoEconomics, 20(SUPPL. 2), 17-23.

The development and use of quality-of-life measures to evaluate health outcomes in Japan. / Fukuhara, Shunichi; Ikegami, Naoki; Torrance, George W.; Nishimura, Shuzo; Drummond, Michael; Schubert, François.

In: PharmacoEconomics, Vol. 20, No. SUPPL. 2, 2002, p. 17-23.

Research output: Contribution to journalArticle

Fukuhara, S, Ikegami, N, Torrance, GW, Nishimura, S, Drummond, M & Schubert, F 2002, 'The development and use of quality-of-life measures to evaluate health outcomes in Japan', PharmacoEconomics, vol. 20, no. SUPPL. 2, pp. 17-23.
Fukuhara S, Ikegami N, Torrance GW, Nishimura S, Drummond M, Schubert F. The development and use of quality-of-life measures to evaluate health outcomes in Japan. PharmacoEconomics. 2002;20(SUPPL. 2):17-23.
Fukuhara, Shunichi ; Ikegami, Naoki ; Torrance, George W. ; Nishimura, Shuzo ; Drummond, Michael ; Schubert, François. / The development and use of quality-of-life measures to evaluate health outcomes in Japan. In: PharmacoEconomics. 2002 ; Vol. 20, No. SUPPL. 2. pp. 17-23.
@article{a2f502cf71de4db395dc55ed2fc55c85,
title = "The development and use of quality-of-life measures to evaluate health outcomes in Japan",
abstract = "Health outcomes measurement forms a key aspect of data collection for economic evaluations. Quality-of-life instruments provide a measure of patient-focused health outcomes. Such instruments, including the EuroQoL questionnaire (EQ-5D) and the Short-form 36 (SF-36) are already being used in Japan. Utility instruments provide an alternative way of measuring quality of life for use in economic analyses. At present, utility measurement in Japan is limited to scores derived from the EQ-5D. Although the SF-36 was designed as a health profile measure, it has since been tested for use as a utility measure, with valuation of items now being undertaken in Japan. Utility measurement in Japan is likely to be advanced further by the validation and introduction of the Health Utilities Index. The experiences of other countries provide the opportunity for Japan to learn how utility scores may be used in cost-utility analyses of healthcare technologies.",
author = "Shunichi Fukuhara and Naoki Ikegami and Torrance, {George W.} and Shuzo Nishimura and Michael Drummond and Fran{\cc}ois Schubert",
year = "2002",
language = "English",
volume = "20",
pages = "17--23",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - The development and use of quality-of-life measures to evaluate health outcomes in Japan

AU - Fukuhara, Shunichi

AU - Ikegami, Naoki

AU - Torrance, George W.

AU - Nishimura, Shuzo

AU - Drummond, Michael

AU - Schubert, François

PY - 2002

Y1 - 2002

N2 - Health outcomes measurement forms a key aspect of data collection for economic evaluations. Quality-of-life instruments provide a measure of patient-focused health outcomes. Such instruments, including the EuroQoL questionnaire (EQ-5D) and the Short-form 36 (SF-36) are already being used in Japan. Utility instruments provide an alternative way of measuring quality of life for use in economic analyses. At present, utility measurement in Japan is limited to scores derived from the EQ-5D. Although the SF-36 was designed as a health profile measure, it has since been tested for use as a utility measure, with valuation of items now being undertaken in Japan. Utility measurement in Japan is likely to be advanced further by the validation and introduction of the Health Utilities Index. The experiences of other countries provide the opportunity for Japan to learn how utility scores may be used in cost-utility analyses of healthcare technologies.

AB - Health outcomes measurement forms a key aspect of data collection for economic evaluations. Quality-of-life instruments provide a measure of patient-focused health outcomes. Such instruments, including the EuroQoL questionnaire (EQ-5D) and the Short-form 36 (SF-36) are already being used in Japan. Utility instruments provide an alternative way of measuring quality of life for use in economic analyses. At present, utility measurement in Japan is limited to scores derived from the EQ-5D. Although the SF-36 was designed as a health profile measure, it has since been tested for use as a utility measure, with valuation of items now being undertaken in Japan. Utility measurement in Japan is likely to be advanced further by the validation and introduction of the Health Utilities Index. The experiences of other countries provide the opportunity for Japan to learn how utility scores may be used in cost-utility analyses of healthcare technologies.

UR - http://www.scopus.com/inward/record.url?scp=0036376509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036376509&partnerID=8YFLogxK

M3 - Article

C2 - 12238945

AN - SCOPUS:0036376509

VL - 20

SP - 17

EP - 23

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - SUPPL. 2

ER -